The emerging data package for Ardelyx Inc.'s first-in-class NH3E inhibitor tenapanor looks competitive with phosphate binders for treating hyperphosphatemia and bodes well for a new Phase III study coming up, analysts say.
Ardelyx is positioning tenapanor for hyperphosphatemia, or high levels of serum phosphorus, associated with end-stage renal disease (ESRD), among other indications
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?